24 May 2013
Keywords: aeterna, reports, strong, data, growth, disorder, drug
Article | 25 April 2005
Canadian oncology and endocrine-focused firm AEterna Zentaris has posted positive results from a Phase I study of its oral growth ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 April 2005
23 May 2013
© 2013 thepharmaletter.com